‘Secret’ negotiations alleged in stumbling block for Carolinas-UNC merger

A board member of UNC Health Care has alleged the health system may have acted illegally by conducting closed-door negotiations on a proposed merger with Carolinas HealthCare System “for the better part of a year” without informing the board. The board’s leaders responded by saying that the member has a conflict of interest and shouldn’t be involved with the deal.

Tom Fetzer, the board member who made the allegations, is a lobbyist for Blue Cross and Blue Shield of North Carolina. Since the combined UNC-Carolinas system would have increased leverage in negotiating with insurance companies, he has previously recused himself from the board’s actions on the merger.

The substance of the allegations, however, could cause problems for the merger. State law, Fetzer said, requires the UNC Health Care System to keep the UNC Board of Governors apprised of any important policy changes. Instead, he said the board was only informed days before the merger plans were publicly announced.

“This is, in my opinion, perhaps the most important health care development in the history of the state of North Carolina,” Fetzer said to the Raleigh News & Observer. “If you kept this deal secret for a year, does that fall within the definition of ‘fully informed?’”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.